<DOC>
	<DOCNO>NCT01637675</DOCNO>
	<brief_summary>Sodium tanshinone IIA sulfonate ( STS ) water-soluble derivative tanshinone IIA isolate main pharmacologically active natural compound traditional Chinese herbal medicine , dry root Salvia miltiorrhiza Bunge know Danshen . Danshen know function improve body function activate blood circulation remove blood stasis accord theory traditional Chinese medicine . Danshen various formula product include STS long-time widely use oriental country , especially China treat various inflammatory cardiovascular disease pharmacological action , include vasodilatation , anticoagulation , anti-inflammation , free radical scavenging , negligible adverse effect observe . The investigator 's objective evaluate whether STS exhibit beneficial effect pulmonary hypertension . This randomize , control , multicentre clinical trial study . 90 patient pulmonary hypertension enrol study .</brief_summary>
	<brief_title>Efficacy Safety Study Sodium Tanshinone IIA Sulfonate Pulmonary Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<mesh_term>Tanshinone</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>1 . Meet condition mean pulmonary arterial pressure ( mPAP ) ≥25 mmHg seal level rest pulmonary capillary wedge pressure ( PCWP ) ≤15mmHg ; 2 . Category 1 4 PH stable stage accord 2008 Dana Point Conference , include idiopathic , hereditary , drug toxin induce , associate connective tissue disease congenital heart disease , chronic thromboembolic pulmonary arterial hypertension ( PAH ) ; 3 . Male female 15 70 year old ; 4. WHO pulmonary hypertension functional class II III ; 5 . The baseline 6minute walk distance 150550 ; 6 . Patients ' condition stable one month basic treatment ; For patient congenital heart disease , surgery perform six month enrol study ; 7 . Patients receive sildenafil treatment previously , without target drug treatment past 3 month ; 8 . Patients guardian agree clinical trail medical inform consent trial sign . 1 . Unavailable limited legal capacity ; 2 . Pregnant lactational woman ; 3 . Important organ severe disease ; 4 . Mental physical disability ; 5 . With suspected indeed alcohol , drug abuse history ; 6 . With allergic constitution , two drug food allergy history allergic component experimental drug ; 7 . With aspartate aminotransferase ( AST ) glutamicpyruvic transaminase ( ALT ) three time upper limit normal liver function test Ccr≤50ml/min kidney function test ; 8 . Those systemic blood pressure＜90/50 mmHg , uncontrolled dangerous hypertension ( BP＞170/110 mmHg ) ; 9 . Patients active stage infectious disease hepatitis A , hepatitis B , AIDS , tuberculosis , connective tissue disease ; 10 . Patients severe infection , especially pulmonary infection ; 11 . Patients shock astable hemodynamics cause ; 12 . Patients hepatic cirrhosis , hepatic cirrhosis induce portal hypertension ; 13 . Patients severe hemorrhage , hemorrhagic tendency ; 14 . Patients need take take drug possible indeed affect trial ; 15 . Patients accomplish require item ( especially 6MWD ) acute/chronic organic disease ( exclude dyspnea ) illnesses low extremity disease ; 16 . Patients condition consider recruit .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>sodium tanshinone IIA sulfonate</keyword>
	<keyword>pulmonary hypertension</keyword>
</DOC>